Announcements

09-Nov-2018

Strides teams up with SUDA Pharma for US market

Strides teams up with SUDA Pharma for US market

Strides Pharma Science Ltd. | 09-Nov-2018

Strides Pharma Science Limited (Strides) on Friday said that its step-down wholly owned subsidiary Strides Pharma Global Pte Limited Singapore has entered into an exclusive product development licensing and supply agreement with SUDA Pharmaceuticals for its novel drug SUD-001Hanoral spray of sumatriptan to treat migraine headache for the US market.

Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway. The company through in house development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period. Today’s announcement of partnership with SUDA is part of company’s specialty portfolio build out for the US market.

Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults. SUD-001His a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand nameImitrex®).

The product will be filed with the USFDA under the 505B (2)regulatory pathway and on approval is expected to be the first fast-acting oral spray of sumatriptan in the US market. The product will utilize SUDA’s recently developed proprietary OroMist®hydrotrope technology that significantly improves the rate of absorption and the quantity of drug that is absorbed across the mucosal membranes.

A primary market assessment on the potential for SUD-001Hfor the treatment of adult migraine confirmed the need fora product that could demonstrate a faster onset of action and the same was supported by medical practitioners.

Strides enters into a strategic partnership with SUDA Pharmaceuticals for the US market

09-Nov-2018

Strides Pharma Scien - Press Release

Strides Pharma Scien - Press Release

Strides Pharma Science Ltd. | 09-Nov-2018

Strides Pharma Science Limited has informed the Exchange regarding a press release dated November 09 2018 titled \Strides enters into a strategic partnership with SUDA Pharmaceuticals for the US market\.

Strides Pharma Science Limited (Strides) on Friday said that its step-down wholly owned subsidiary Strides Pharma Global Pte Limited Singapore has entered into an exclusive product development licensing and supply agreement with SUDA Pharmaceuticals for its novel drug SUD-001Hanoral spray of sumatriptan to treat migraine headache for the US market.

Execution of Strides’ generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway. The company through in house development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period. Today’s announcement of partnership with SUDA is part of company’s specialty portfolio build out for the US market.

Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults. SUD-001His a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand nameImitrex®).

The product will be filed with the USFDA under the 505B (2)regulatory pathway and on approval is expected to be the first fast-acting oral spray of sumatriptan in the US market. The product will utilize SUDA’s recently developed proprietary OroMist®hydrotrope technology that significantly improves the rate of absorption and the quantity of drug that is absorbed across the mucosal membranes.

A primary market assessment on the potential for SUD-001Hfor the treatment of adult migraine confirmed the need fora product that could demonstrate a faster onset of action and the same was supported by medical practitioners.

Make smart investment decisions with Star Ratings, a stock selection tool, based upon fundamental, technical and analyst recommendations. Star Ratings provides stock trading tips for Strides Pharma Science Ltd. that will help you decide whether to buy, sell or hold Strides Pharma Science Ltd. It also provides you with switch proposals on alternative stocks, i.e., which stocks to buy against Strides Pharma Science Ltd.

Prevent unauthorized transactions in your account - Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day - Issued in the interest of Investors.

Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from Depository (NSDL/CDSL) on the same day issued in the interest of investors.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investors account.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Trading and Demat Accounts opened under Insta Plan will not be eligible for dealing through branches.